The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 20, 2018

Filed:

Dec. 18, 2015
Applicants:

Jamie Singer, Knoxville, TN (US);

Eric Wachter, Oak Ridge, TN (US);

Amod Sarnaik, Tampa, FL (US);

Shari Pilon-thomas, Tampa, FL (US);

Hao Liu, Tampa, FL (US);

Inventors:

Jamie Singer, Knoxville, TN (US);

Eric Wachter, Oak Ridge, TN (US);

Amod Sarnaik, Tampa, FL (US);

Shari Pilon-Thomas, Tampa, FL (US);

Hao Liu, Tampa, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/21 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C12P 21/00 (2006.01); A61K 31/352 (2006.01); C12P 21/02 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/352 (2013.01); A61K 35/15 (2013.01); A61K 38/1709 (2013.01); A61K 38/217 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); C07K 16/2803 (2013.01); C12P 21/005 (2013.01); C12P 21/02 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/76 (2013.01);
Abstract

A cancer immunotherapy method is disclosed in which 'induced immune anticancer agents' are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.


Find Patent Forward Citations

Loading…